From Firecebiotech.com:
Dimension Therapeutics is preparing to execute the next carefully planned step in its evolution, filing for a $115 million IPO close to 5 months after its crossover round landed. The filing came just days after the FDA accepted Cambridge, MA-based Dimension's IND for its lead gene therapy program, targeting a genetic fix for hemophilia B.
Dimension's lead program for DTX101 uses an AAV vector to deliver Factor IX into hemophilia patients. It's one of several biotechs to focus their first gene therapy programs on hemophilia, which a number of experts believe makes a logical focus for the new wave of upstarts now working in the field.
Gene therapy has been booming over the past two years as developers like bluebird bio ($BLUE) have powered their way back in after the first generation of work was shelved following the emergence of lethal side effects. Biogen ($BIIB) focused its new gene therapy group on hemophilia, alongside Spark Therapeutics ($ONCE), RegenX--which outlicensed original tech to Dimension--and others. But for now there's more promise than performance, as new data start to reveal whether a single-dose fix can work safely.
http://www.fiercebiotech.com/story/gene-therapy-player-dimension-catches-biotech-ipo-wave-files-115m-offering/2015-09-14
No comments:
Post a Comment